1
Conclusions: Traditional CHM does not reduce the hematologic toxicity associated with chemotherapy.
2
Neurotoxicity and hematologic toxicity were more severe on the higher dose arms.
3
Of note, little severe hematologic toxicity and no significant headaches were reported.
4
The remaining trials reported on hematologic toxicity in 16 different ways.
5
Clinically significant myelosuppression was not observed; hematologic toxicity was generally mild and reversible.
6
Furthermore, hematologic toxicity was extremely mild and appeared not to be dose dependent.
7
No dose reductions, delays, or discontinuations were required for hematologic toxicity.
8
In all cases, hematologic toxicity was short term and reversible.
9
Results: We identified five PCs associated with acute hematologic toxicity.
10
Therapy was well tolerated with the expected reversible hematologic toxicity.
11
CSFs can, however, reduce the hematologic toxicity of chemotherapy, which represents the most significant result.
12
Toxic effects included moderate hematologic toxicity, nausea, and vomiting.
13
All patients evaluable for hematologic toxicity developed grade 4 neutropenia and thrombocytopenia during protocol therapy.
14
Although manageable in an oncology setting, the hematologic toxicity of such a regimen remains substantial.
15
Significant hematologic toxicity was observed and was not obviously related to the dose of trimetrexate.
16
Major toxicities included hematologic toxicity, mucositis and infectious complications.
